Interpreting the pattern of the pediatric medicine market, the track overtaking focuses on the segmentation

At a press conference held by the National Health Commission on August 25, Jiang Jiandong, president of the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences and academician of the Chinese Academy of Engineering, introduced that in 2021, a total of 47 children's drugs will be approved for marketing

Recently, the investment actions and attention related to pediatric drugs are also quite high

There is a great market demand for children's medicine, and it is more related to the healthy growth of the next generation in the motherland, which has far-reaching social significance

Anatomy of the current market situation

Tempting 100 billion market

According to data, the size of China's children's drug market will be about

However, in the pediatric drug market, many drugs are appropriate reductions for adult drugs, typical such as lung cancer treatment drugs, basically there is no special research and development for children, and the basic use of children's lung cancer patients is adult drugs

Even the scale of the children's drug market of about 100 billion yuan calculated by Founder Securities is very large, and there should be many enterprises investing and participating, but this is not the case

R&D problem solving

Pediatric medicine has always been a difficult field

These basic underlying logics pose great challenges

Low-key multinational pharmaceutical companies

From the perspective of manufacturers, it can be divided into international enterprises and domestic enterprises

From this, it can be summarized that the layout characteristics of pediatric drugs of multinational pharmaceutical companies can be summarized: 1.

Local enterprises

Among the domestic pharmaceutical companies, the largest pediatric pharmaceutical enterprise is Changchun Jinsai, and most of the 8.

In addition, domestic enterprises also include traditional representative enterprises such as Yabao Pharmaceutical, Renhe Pharmaceutical, Jianmin Group, Dyne Pharmaceutical, Hansen Pharmaceutical, Huluwa Pharmaceutical, Guizhou Sanli, and other traditional representative enterprises, as well as biopharmaceutical enterprises

It is also worth mentioning the field of children's vision protection, typical representatives such as OPCOM Vision

Summarize the characteristics of the pediatric drug layout of domestic pharmaceutical companies as follows: 1.

Essentials of enterprise layout

From the perspective of the types of drugs, the diseases with a high prevalence of children in China are mainly respiratory diseases and digestive system diseases, and further subdivided according to the type of disease are colds, fevers, coughs, dyspepsia (constipation, etc.

So, what are the opportunities and risks for enterprises that want to increase the field of pediatric drugs?

Giants are expected to be born

The underlying logic of the pediatric drug market opportunity lies in the huge Chinese market, the increasingly wealthy people's emphasis on children's health, and the government's continuous attention and investment in this field and the advantages of

Of course, focusing on pediatric medicine does not mean only doing pediatric medicine, but can expand to other fields based on the accumulated technology and resources of pediatric drugs, just like international mature pharmaceutical companies expand
from adult medicines to pediatric drugs.
Kinsey is a typical example, in addition to pediatric drugs, it has been expanding
to tumor immunology, gynecology, geriatric diseases and so on.

After the wave judged the situation

In the field of common diseases such as breathing and digestion, pediatric medicine has a strong brand effect, such as the small sunflower of sunflower, the 999 of China Resources Sanjiu, and the Yi kexin of Dyne Pharmaceutical
.
This is a natural moat for businesses that already have brand and channel advantages
.
Similar products of latecomer enterprises, if there is no obvious product advantage, it is difficult to PK with existing brands: not only to seize the minds of doctors, but also to seize the minds of end consumers, and the investment is large and the effect is limited
.
For new entrants, if there is no unique product advantage, common diseases are areas
that should be avoided.

Segment opportunity areas

Where are the new opportunities? The answer is segmentation
.

One clear opportunity is the prevention and treatment of myopia in
children.
For example, the children's orthokeratology (commonly known as OK mirror) market is still dominated by European, American, Korean and Japanese manufacturers, and the market is still growing
.
This means that there are still great opportunities for domestic substitution for enterprises like OPCOM, and the story of combining model innovation through technological breakthroughs and model innovation, from follow-up to leadership, has been staged
countless times in the Chinese market.

Children's short stature or growth disorders, rare diseases in children, and children's mental illnesses caused by various reasons are also worthy of attention
.
The former already has a kinsey success story, and the market is far from mature, with the domestic market awareness, academic promotion efforts, clinical recognition and patient consumption capacity to improve, the market still has the opportunity for
new entrants.

Rare diseases are the track that has attracted more attention in recent years, according to the "Zhejiang Province Rare Disease Patients Living Conditions and Disease Burden Research Project Phased Report" data released in 2021, among the 121 rare diseases in the national rare disease directory, there are many
types of rare diseases in children.

In addition, there is a large number of unmet needs
in the market for childhood mental illnesses, such as autism.

R&D breakthroughs in these fields not only have a strong social effect, but also a strong economic effect
.